我领导着一个由转化科学家组成的团队，他们研究澳门第一赌城在线娱乐的肿瘤驱动因素和耐药性项目, DNA damage response and epigenetics portfolio. We study tumour biology, 通过尖端技术推动临床试验设计创新，加快临床决策.

Before joining AstraZeneca in October 2020, 我是纪念斯隆凯特琳癌症中心的副教授兼转化科学副主任. 在这个职位上，我与早期药物开发医生密切合作，使临床的新发现和假设能够在实验室环境中快速评估.

我的研究兴趣一直集中在阐明肿瘤脆弱性以改善患者选择以及靶向治疗施加的选择压力如何影响耐药性. 我早期研究的亮点包括确定对PI3K抑制剂和抗her2治疗的耐药机制. 我还研究了在实体肿瘤中发现的可操作的基因组改变的特征，这促使了新的治疗策略的测试.

In my team at AstraZeneca, 澳门第一赌城在线娱乐为设计新的组合策略和识别对治疗反应的生物标志物提供科学依据. 澳门第一赌城在线娱乐专注于澳门第一赌城在线娱乐的肿瘤驱动因素和抵抗力的资产策略, DNA损伤反应与表观遗传学科学平台.

我热衷于弥合诊所和实验室之间的差距，为癌症患者带来新的治疗选择

Maurizio Scaltriti 早期肿瘤学转化医学副总裁

2015

Tory Burch奖(乳腺癌研究基金会)

2014

AACR早期职业演讲奖(NextGen Star)

2010

AACR-Susan G. Komen Scholar-in-Training Award

CURRENT ROLE

加入澳门在线赌城娱乐，担任早期肿瘤学转化医学副总裁

2020

加入澳门在线赌城娱乐，担任早期肿瘤学转化医学副总裁&D

2016

被任命为分子治疗中心转化科学副主任, Memorial Sloan Kettering Cancer Center

2013

加入纪念斯隆凯特琳癌症中心担任助理教授

Career highlights

2015

Approval of first DDR medicine, 肿瘤学创新与成就奖“优胜者中的优胜者”

2009, 2015

戈登哺乳动物DNA修复研究会议在文图拉举行

2009, 2015

辅助诊断测试被批准用于激活EGFR-TK突变，以指导肺癌的治疗

Featured publications

Expression of p95HER2, a truncated form of the HER2 receptor, 以及乳腺癌患者对抗her2疗法的反应

Scaltriti M, Rojo F, Ocaña A, Anido J, Guzman M, Cortes J, Di Cosimo S, Matias-Guiu X, Ramon y Cajal S, Arribas J, Baselga J. Expression of p95HER2, a truncated form of the HER2 receptor, 以及乳腺癌患者对抗her2疗法的反应. J Natl Cancer Inst. 2007 Apr 18;99(8):628-38. doi: 10.1093/jnci/djk134 
Link: http://pubmed.ncbi.nlm.nih.gov/17440164/

Lapatinib, a HER2 tyrosine kinase inhibitor, 诱导HER2的稳定和积累，增强曲妥珠单抗依赖的细胞毒性

Scaltriti M, Verma C, Guzman M, Jimenez J, Parra JL, Pedersen K, Smith DJ, Landolfi S, Ramon y Cajal S, Arribas J, Baselga J. Lapatinib, a HER2 tyrosine kinase inhibitor, 诱导HER2的稳定和积累，增强曲妥珠单抗依赖的细胞毒性. Oncogene. 2009 Feb 12;28(6):803-14. doi: 10.1038/onc.2008.432. Epub 2008 Dec 8.

拉帕替尼治疗人表皮生长因子受体2阳性乳腺癌共表达p95HER2受体的临床疗效

Scaltriti M, Chandarlapaty S, Prudkin L, Aura C, Jimenez J, Angelini PD, Sánchez G, Guzman M, Parra JL, Ellis C, Gagnon R, Koehler M, Gomez H, Geyer C, Cameron D, Arribas J, Rosen N, Baselga J. 拉帕替尼治疗人表皮生长因子受体2阳性乳腺癌共表达p95HER2受体的临床疗效. Clin Cancer Res. 2010 May 1;16(9):2688-95. doi: 10.1158/1078-0432.CCR-09-3407. Epub 2010 Apr 20.

ERBB2扩增或突变肺癌中her2介导的细胞毒性药物内化

Li BT, Michelini F, Misale S, Cocco E, Baldino L, Cai Y, Shifman S, Tu HY, Myers ML, Xu C, Mattar M, Khodos I, Little M, Qeriqi B, Weitsman G, Wilhem CJ, Lalani AS, Diala I, Freedman RA, Lin NU, Solit DB, Berger MF, Barber PR, Ng T, Offin M, Isbell JM, Jones DR, Yu HA, Thyparambil S, Liao WL, Bhalkikar A, Cecchi F, Hyman DM, Lewis JS, Buonocore DJ, Ho AL, Makker V, Reis-Filho JS, Razavi P, Arcila ME, Kris MG, Poirier JT, Shen R, Tsurutani J, Ulaner GA, de Stanchina E, Rosen N, Rudin CM, Scaltriti M. her2介导的细胞毒性药物内化 ERBB2 Amplified or Mutant Lung Cancers. Cancer Discov. 2020 May;10(5):674-687. doi: 10.1158/2159-8290.CD-20-0215. Epub 2020 Mar 25
Link: http://pubmed.ncbi.nlm.nih.gov/32213539/

PTEN的收敛性丢失导致对PI(3)Kα抑制剂的临床耐药


Juric D, Castel P, Griffith M, Griffith OL, Won HH, Ellis H, Ebbesen SH, Ainscough BJ, Ramu A, Iyer G, Shah RH, Huynh T, Mino-Kenudson M, Sgroi D, Isakoff S, Thabet A, Elamine L, Solit DB, Lowe SW, Quadt C, Peters M, Derti A, Schegel R, Huang A, Mardis ER, Berger MF, Baselga J, Scaltriti M. PTEN的收敛性丢失导致对PI(3)Kα抑制剂的临床耐药. Nature. 2015 Feb 12;518(7538):240-4. doi: 10.1038/nature13948. Epub 2014 Nov 17. 
Link: http://pubmed.ncbi.nlm.nih.gov/25409150/

PDK1-SGK1信号传导维持akt非依赖性mTORC1激活并赋予PI3Kα抑制的抗性

Castel P, Ellis H, Bago R, Toska E, Razavi P, Carmona FJ, Kannan S, Verma CS, Dickler M, Chandarlapaty S, Brogi E, Alessi DR, Baselga J, Scaltriti M. PDK1-SGK1信号传导维持akt非依赖性mTORC1激活并赋予PI3Kα抑制的抗性. Cancer Cell. 2016 Aug 8;30(2):229-242. doi: 10.1016/j.ccell.2016.06.004. Epub 2016 Jul 21.
Link: http://pubmed.ncbi.nlm.nih.gov/27451907/

PI3K抑制导致激素受体阳性乳腺癌雌激素受体功能增强和依赖性

Bosch A, Li Z, Bergamaschi A, Ellis H, Toska E, Prat A, Tao JJ, Spratt DE, Viola-Villegas NT, Castel P, Minuesa G, Morse N, Rodón J, Ibrahim Y, Cortes J, Perez-Garcia J, Galvan P, Grueso J, Guzman M, Katzenellenbogen JA, Kharas M, Lewis JS, Dickler M, Serra V, Rosen N, Chandarlapaty S, Scaltriti M, Baselga J. PI3K抑制导致激素受体阳性乳腺癌雌激素受体功能增强和依赖性. Sci Transl Med. 2015 Apr 15;7(283):283ra51. doi: 10.1126/scitranslmed.aaa4442. Erratum in: Sci Transl Med. 2018 Oct 24;10(464)
Link: http://pubmed.ncbi.nlm.nih.gov/25877889/

FOXA1突变揭示了不同的染色质谱并影响乳腺癌的治疗反应

Arruabarrena-Aristorena A, Maag JLV, Kittane S, Cai Y, Karthaus WR, Ladewig E, Park J, Kannan S, Ferrando L, Cocco E, Ho SY, Tan DS, Sallaku M, Wu F, Acevedo B, Selenica P, Ross DS, Witkin M, Sawyers CL, Reis-Filho JS, Verma CS, Jauch R, Koche R, Baselga J, Razavi P, Toska E, Scaltriti M. FOXA1突变揭示了不同的染色质谱并影响乳腺癌的治疗反应. Cancer Cell. 2020 Oct 12;38(4):534-550.e9. doi: 10.1016/j.ccell.2020.08.003. Epub 2020 Sep 3.
Link: http://pubmed.ncbi.nlm.nih.gov/32888433/

趋同MAPK通路激活介导的TRK抑制抗性

Cocco E, Schram AM, Kulick A, Misale S, Won HH, Yaeger R, Razavi P, Ptashkin R, Hechtman JF, Toska E, Cownie J, Somwar R, Shifman S, Mattar M, Selçuklu SD, Samoila A, Guzman S, Tuch BB, Ebata K, de Stanchina E, Nagy RJ, Lanman RB, Houck-Loomis B, Patel JA, Berger MF, Ladanyi M, Hyman DM, Drilon A, Scaltriti M. 趋同MAPK通路激活介导的TRK抑制抗性. Nat Med. 2019 Sep;25(9):1422-1427. doi: 10.1038/s41591-019-0542-z. Epub 2019 Aug 12.
Link: http://pubmed.ncbi.nlm.nih.gov/31406350/

TRK xDFG突变触发从I型到II型激酶抑制剂的敏感性转换.

Cocco E, Lee JE, Kannan S, Schram AM, Won HH, Shifman S, Kulick A, Baldino L, Toska E, Arruabarrena-Aristorena A, Kittane S, Wu F, Cai Y, Arena S, Mussolin B, Kannan R, Vasan N, Gorelick AN, Berger MF, Novoplansky O, Jagadeeshan S, Liao Y, Rix U, Misale S, Taylor BS, Bardelli A, Hechtman JF, Hyman DM, Elkabets M, de Stanchina E, Verma CS, Ventura A, Drilon A, Scaltriti M. TRK xDFG突变触发从I型到II型激酶抑制剂的敏感性转换. Cancer Discov. 2021 Jan;11(1):126-141. doi: 10.1158/2159-8290.CD-20-0571. Epub 2020 Oct 1.
Link: http://pubmed.ncbi.nlm.nih.gov/33004339/

Veeva ID: Z4-45787
Date of preparation: June 2022